Disclosures for "Trends and Predictors of Peripheral CD19+ B-cell Repopulation in Patients Treated with Ocrelizumab during COVID-19 Pandemic")
-
Dr. Padron has nothing to disclose.
-
Ms. Jimsheleishvili has nothing to disclose.
-
Dr. Tornes has nothing to disclose.
-
Dr. Delgado has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Delgado has received research support from Novartis. The institution of Dr. Delgado has received research support from EMD Serono. The institution of Dr. Delgado has received research support from NIH/NINDS.
-
Dr. Garg has nothing to disclose.